Avalo Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Avalo Therapeutics, Inc. (Nasdaq: AVTX) is a clinical-stage biotechnology company fully dedicated to developing IL-1̂-based treatments for immune-mediated inflammatory diseases. The company's lead asset is abdakibart (formerly AVTX-009), a high-affinity, highly potent humanized IgG4 monoclonal antibody designed to specifically inhibit IL-1̂ and block downstream inflammatory pathways. Abdakibart is currently being evaluated for the treatment of hidradenitis suppurativa (HS). Avalo's pipeline also includes AVTX-010, a long-acting next-generation anti-IL-1̂ monoclonal antibody designed to extend dosing intervals, alongside other early-stage assets such as quisovalimab (anti-LIGHT mAb) and AVTX-008.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing abdakibart, an anti-IL-1̒ monoclonal antibody, into a Phase 3 registrational program for moderate to severe hidradenitis suppurativa (HS).
Expected impact: Aims to establish a best-in-class and best-in-disease therapeutic profile for HS, targeting a multi-billion-dollar market.
Developing AVTX-010, a long-acting next-generation anti-IL-1̒ monoclonal antibody designed to extend dosing intervals and enhance intellectual property, complementing the abdakibart program.
Expected impact: Provides a patient-friendly extended dosing profile with fewer injections for HS and other inflammatory disorders.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired to obtain abdakibart (AVTX-009), a Phase 2-ready anti-IL-1̒ monoclonal antibody with potential in hidradenitis suppurativa and other inflammatory diseases.
Financial impact: Structured as a stock-for-stock transaction valued at $15 million plus a $7.5 million upfront cash payment. In April 2026, Avalo entered into a Milestone Buyout Option and Amendment Agreement, paying $2.25 million for an option to pay $5.125 million in lieu of a previously agreed $15 million Phase 3 dosing milestone.
Strategic Partnerships
Out-licensed the rights to research, develop, manufacture, and commercialize AVTX-007 (camoteskimab), Avalo's anti-IL-18 monoclonal antibody, allowing Avalo to focus resources on its core pipeline [2.4.1].
Terms: Avalo received a $5 million upfront fee and approximately $10 million for transfer activities. Avalo is also eligible to receive up to $74 million in milestone payments plus low single-digit royalties on annual net sales.